Hospital
Community Hospitals and Wellness Centers
Community Hospitals and Wellness Centers was paid $7.29M by Medicaid between Jan 2018 and Dec 2024, across 188 billing codes. Its largest line is 99283, emergency room visit (moderate) — 19% of everything it billed.
33Billing provider infoCOMMUNITY HOSPITALS AND WELLNESS CENTERS
BRYAN, OH 43506
BRYAN, OH 43506
33aNPI1962458521assigned 05/25/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$7.29M
24GClaims227,118
24DCodes billed188
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Ohio
Rank by total paid#83 of 101
Median peer was paid$22.32M
This provider vs. median0.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official RISSER, STANTON controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 12,906 | $399K | |
| 2019 | 12,666 | $427K | |
| 2020 | 11,250 | $463K | |
| 2021 | 20,799 | $697K | |
| 2022 | 27,581 | $976K | |
| 2023 | 92,207 | $2.74M | |
| 2024incomplete | 49,709 | $1.59M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 19% | 12,947 | 11,350 | $1.41M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 7,388 | 5,446 | $867K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 7.2% | 4,286 | 3,208 | $528K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.4% | 3,699 | 2,559 | $463K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.9% | 2,736 | 2,442 | $281K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 3.8% | 1,136 | 686 | $277K |
| 96361 | Intravenous infusion, hydration; each additional hour | 3.8% | 958 | 600 | $277K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.8% | 1,134 | 738 | $275K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.6% | 1,133 | 836 | $264K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 3.5% | 4,042 | 3,453 | $253K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 3.0% | 919 | 618 | $218K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2.6% | 5,087 | 4,242 | $193K |
176 more codes
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.3% | 1,815 | $165K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 2.2% | 4,286 | $161K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 2.2% | 1,242 | $157K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.1% | 2,464 | $156K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.6% | 1,713 | $118K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.3% | 642 | $98K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.1% | 1,073 | $83K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.1% | 596 | $81K |
| G0378 | Hospital observation service, per hour | 1.1% | 972 | $77K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 1,456 | $67K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 12,357 | $64K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 319 | $51K |
| 80053 | Comprehensive metabolic panel | <1% | 4,650 | $36K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 120 | $35K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,029 | $33K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 444 | $30K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 4,727 | $27K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 709 | $26K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 377 | $25K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 105 | $25K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 230 | $23K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 17,400 | $22K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 105 | $20K |
| 64493 | <1% | 29 | $19K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 17,183 | $18K |
| 87631 | <1% | 111 | $17K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 441 | $15K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,656 | $14K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,189 | $14K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,861 | $13K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 707 | $13K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 161 | $13K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 52 | $13K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 46 | $11K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 58 | $11K |
| 71045 | Radiologic examination, chest; single view | <1% | 5,912 | $10K |
| 80306 | <1% | 1,142 | $9K | |
| J3490 | Unclassified drugs | <1% | 2,791 | $9K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,120 | $8K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 64 | $8K |
| 96367 | <1% | 47 | $7K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,422 | $7K |
| 97161 | <1% | 148 | $6K | |
| 85027 | <1% | 925 | $6K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 288 | $5K |
| 84484 | <1% | 3,833 | $5K | |
| 87081 | <1% | 908 | $5K | |
| 80061 | Lipid panel | <1% | 446 | $5K |
| 73562 | <1% | 180 | $5K | |
| 80320 | <1% | 681 | $5K | |
| 73630 | <1% | 244 | $5K | |
| 86140 | <1% | 2,066 | $5K | |
| 84439 | <1% | 379 | $4K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 326 | $4K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 421 | $4K |
| 80076 | <1% | 2,127 | $4K | |
| 81001 | <1% | 4,219 | $4K | |
| 82728 | <1% | 254 | $4K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 482 | $4K |
| 99223 | Prolong inpt eval add15 m | <1% | 91 | $4K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 155 | $3K |
| 84702 | <1% | 200 | $3K | |
| 84703 | <1% | 2,701 | $3K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 50 | $3K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 148 | $3K |
| 83735 | <1% | 1,750 | $3K | |
| 76830 | Ultrasound, transvaginal | <1% | 113 | $3K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,028 | $3K |
| 73130 | <1% | 102 | $3K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 15 | $3K |
| 83540 | <1% | 289 | $3K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 130 | $3K |
| 83605 | <1% | 1,318 | $3K | |
| 73030 | <1% | 121 | $2K | |
| 82607 | <1% | 109 | $2K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,631 | $2K |
| 85610 | <1% | 1,254 | $2K | |
| 82805 | <1% | 47 | $2K | |
| 83880 | <1% | 1,222 | $2K | |
| 81003 | <1% | 1,323 | $2K | |
| 83550 | <1% | 230 | $2K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 35 | $2K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 95 | $2K |
| 83690 | <1% | 4,079 | $2K | |
| 73610 | <1% | 107 | $2K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 62 | $2K |
| 82962 | <1% | 1,344 | $1K | |
| 00170 | Anesthesia for intraoral procedures, including biopsy | <1% | 13 | $1K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 14 | $1K |
| 85379 | <1% | 825 | $1K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 19 | $1K |
| 87806 | <1% | 34 | $1K | |
| 86592 | <1% | 47 | $1K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 57 | $1K |
| 95165 | Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials | <1% | 13 | $982.10 |
| 87150 | <1% | 17 | $946.40 | |
| 00731 | <1% | 15 | $892.65 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,007 | $870.74 |
| 87186 | <1% | 303 | $865.09 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 137 | $843.21 |
| 86850 | <1% | 47 | $804.77 | |
| 93971 | <1% | 13 | $803.57 | |
| 74022 | <1% | 339 | $761.39 | |
| 87077 | <1% | 227 | $668.28 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 6,833 | $632.61 |
| 72100 | <1% | 12 | $620.48 | |
| 85651 | <1% | 218 | $582.02 | |
| 85730 | <1% | 961 | $545.58 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 44 | $541.85 |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 43 | $523.42 |
| 86900 | <1% | 92 | $513.66 | |
| 74018 | <1% | 56 | $435.94 | |
| 96376 | <1% | 313 | $424.80 | |
| 36591 | <1% | 143 | $421.59 | |
| 80055 | <1% | 12 | $410.96 | |
| 73110 | <1% | 12 | $304.87 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,907 | $301.29 |
| 87101 | <1% | 12 | $297.25 | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 45 | $292.90 |
| 82565 | <1% | 37 | $275.75 | |
| 86901 | <1% | 92 | $257.97 | |
| 80143 | <1% | 159 | $252.61 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 769 | $227.00 |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 17 | $213.78 |
| J2704 | Injection, propofol, 10 mg | <1% | 4,889 | $195.60 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 729 | $154.56 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 236 | $153.16 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 202 | $140.84 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,081 | $123.62 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 629 | $88.80 |
| 84481 | <1% | 27 | $85.32 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 492 | $73.40 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,556 | $70.26 |
| 84460 | <1% | 614 | $61.99 | |
| 87040 | <1% | 281 | $58.90 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,442 | $50.74 |
| 84450 | <1% | 630 | $48.63 | |
| 82247 | <1% | 516 | $43.15 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,825 | $39.44 |
| 84075 | <1% | 532 | $39.35 | |
| 83615 | <1% | 14 | $35.64 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,394 | $34.30 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 656 | $34.05 |
| 80179 | <1% | 137 | $33.02 | |
| 87070 | <1% | 40 | $32.90 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,191 | $28.44 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 55 | $25.32 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 145 | $21.84 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 548 | $15.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 31 | $13.50 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 420 | $10.77 |
| J7799 | Noc drugs, other than inhalation drugs, administered through dme | <1% | 29 | $9.84 |
| C1729 | Catheter, drainage | <1% | 28 | $9.33 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 959 | $9.00 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 137 | $2.10 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 817 | $2.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 302 | $0.34 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 255 | $0.00 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 247 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 25 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 208 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 78 | $0.00 |
| G8730 | Pain assessment documented as positive using a standardized tool and a follow-up plan is documented | 0% | 77 | $0.00 |
| G9578 | Documentation of signed opioid treatment agreement at least once during opioid therapy | 0% | 17 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 42 | $0.00 |
| 1006F | 0% | 28 | $0.00 | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 296 | $0.00 |
| 64494 | 0% | 29 | $0.00 | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | 0% | 12 | $0.00 |
| 88304 | 0% | 188 | $0.00 | |
| A9270 | Non-covered item or service | 0% | 44 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 36 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 12 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 24 | $0.00 |
| 82150 | 0% | 27 | $0.00 | |
| J1815 | Injection, insulin, per 5 units | 0% | 21 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRISSER, STANTON (ACFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.